Study on explaining cancer drug benefits and risks
Part of Cancer clinical trials.
This study looks at how to explain the benefits and risks of new cancer drugs in a way that is easier to understand. It helps researchers learn how to communicate better with patients like you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You are fluent in English.
- You live in the United States.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This survey asks people who have had cancer about what they expect from new cancer drugs—especially ones approved based on slowing tumor growth (rather than helping people live longer). Your answers could help shape how these drugs are evaluated.
This trial asks cancer patients about their thoughts on new cancer drugs and what they would prefer in treatment. You'll fill out a short survey to share your views.
This study tests a digital tool that uses pictures and simple visuals to help you understand your cancer treatment options. The goal is to make the experience better for you, your family, and your doctors.
This study looks at how doctors and patients talk about clinical trials, with the goal of improving conversations for everyone involved. If you join, you'll fill out questionnaires about your experiences.
This British Columbia study looks at how well different cancer treatments work in real life when doctors aren't sure which option is best. You and your doctor would choose a treatment, and researchers will track your results to help others.
This study looks at how teens and young adults with tough-to-treat cancers, and their families, want to hear news about their cancer. It will help doctors learn the best ways to share information during check-ups and scans.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.